Breast cancer
Management of HER2+ MBC
Obiettivo della formazione: Gain insight into the appropriateness of systemic therapies for patients with HER2+ metastatic breast cancer (MBC), mainly focussing on patients without brain metastases.
Specializzazione: Medical oncology, Clinical oncology
Pubblico target: CME (basic, intermediate), Residents (senior)
Aggiornamento più recente: November 2023
Premessa:
In a short window of time, new drugs for HER2+ MBC have become available. This created both clinical opportunity and uncertainty regarding the selection and sequencing of therapy.
Regulatory approval status of targeted therapies for HER2+ MBC (indications limited to HER2+ MBC setting, status 3 October 2023)
